Master of Science in Dentistry
Parthasarathy A. Madurantakam, D.D.S., M.D.S., Ph.D.
Da Huang Ph.D.
Hu Yang Ph.D.
Thomas C. Waldrop, D.D.S., M.S.
Purpose: Prescription of a complete course of oral antibiotics following bone grafting procedures is a common clinical practice in surgical periodontics. Prophylactic administration of antibiotics reduces the risk of surgical site infection and systemic administration is preferred over local delivery because of short duration of action in the latter circumstance. The goal of this study is to demonstrate the ability of dendrimer hydrogels (DH) to prolong the release kinetics of antibiotics in-vitro. A secondary goal will be to analyze the effect of different particulate bone allografts on the release kinetics of the antibiotic.
Methods: Dendrimer hydrogels (DH) were synthesized from polyamidoamine (PAMAM) G5 and polyethylene glycol diacrylate (PEG-DA) to contain Cefazolin, a first-generation cephalosporin antibiotic, for these in-vitro experiments. Two different types of allogeneic bone grafts (demineralized freeze-dried or freeze-dried) along with a negative control (no bone graft) were used to study the effects of bone graft on the release kinetics of cefazolin. Samples were bathed in PBS and incubated at 37o Celsius while 1mL aliquots were taken at time points 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 12hrs, 24hrs, 48hrs, 72hrs. Aliquots were analyzed using HPLC and a standard curve was used to determine the concentration of cefazolin in each sample.
Results: The estimated maximum concentration of cefazolin in samples containing DH was 36.97mcg/mL (95% CI: 34.58-39.36) with 50% released in 4.17 hours (95%: 3.26-5.07) and an estimated growth rate of 0.27 (95% CI: 0.17-0.37). For samples without DH, estimated maximum concentration of cefazolin was 167.4mcg/mL (95% CI: 160.4-174.4) with 50% released in 2.36 hours (95% CI: 2.05-2.67) and an estimated growth rate of 0.70 (95% CI: 0.54-0.87). Bone grafts did not significantly affect the release of cefazolin in this experiment.
Conclusion: DH is a promising platform for long-term release of cefazolin in-vitro.
© The Author
Is Part Of
VCU University Archives
Is Part Of
VCU Theses and Dissertations
Date of Submission